Klin Farmakol Farm. 2016;30(4):19-23 | DOI: 10.36290/far.2016.030

Antiepileptic drug interactions. Part 1: Mutual interactions between antiepileptic drugs

Blanka Kořístková1,2, Milan Grundmann1
Ústav klinické farmakologie, Lékařská fakulta, Ostravská Univerzita, Ostrava; 1
Oddělení klinické farmakologie, Ústav laboratorní diagnostiky, Fakultní nemocnice Ostrava; 2

Pharmacokinetic interactions between antiepileptic drugs are associated with enzymatic induction or inhibition. Felbamate, clobazam,
lamotrigine, stiripentol, and sulthiame are significant inhibitors. Felbamate increases the levels of clonazepam, lamotrigine,
mesuximide, valproic acid, and the active S(+)-enantiomer vigabatrin. Clobazam increases the levels of stiripentol, carbamazepine,
and carbamazepine-10,11-epoxide. Stiripentol increases the levels of ethosuximide, phenobarbital, carbamazepine, clobazam and
N-desmethylclobazam, primidone, and valproate. Acetazolamide, felbamate, phenytoin, mesuximide, oxcarbazepine, rufinamide,
and sulthiame increase the levels of phenobarbital and phenytoin. The level of phenytoin is also increased by eslicarbazepine,
clobazam, stiripentol, and topiramate. Phenobarbital and lamotrigine increase the AUC of retigabine. Valproic acid increases the
levels of phenobarbital, lamotrigine, and rufinamide, while reducing the levels of felbamate and topiramate. It may decrease,
increase as well as not affect the levels of ethosuximide, phenytoin, and carbamazepine.
Eslicarbazepine, carbamazepine, phenytoin, phenobarbital, mesuximide, oxcarbazepine, primidone, and vigabatrin are enzymatic
inductors. A reduction in levels due to induction may occur with eslicarbazepine, ethoxusimide, phenytoin, felbamate, phenobarbital, clobazam, clonazepam, lacosamide, lamotrigine, levetiracetam, oxcarbazepine including its metabolite, perampanel,
pregabalin, primidone, retigabine, rufinamide, stiripentol, sulthiame, tiagabine, topiramate, valproate, and zonisamide. Pregabalin
increases the clearance of tiagabine and topiramate. Retigabine reduces the AUC of phenobarbital.
Interactions involving absorption, distribution, or excretion are less frequent: acetazolamide reduces the absorption of primidone.
Phenobarbital increases the free fraction of valproate, while valproate increases that of phenytoin and oxcarbazepine. Gabapentin
decreases the excretion of felbamate.
Adverse pharmacodynamic interactions involve side effects: concomitant treatment with agents acting at the sodium channel
increases the risk of neurotoxicity. During the administration of lamotrigine with valproate, tremor can occur and the risk of skin
rash and Stevens-Johnson syndrome increases. The incidence of encephalopathy after valproate increases when it is combined
with topiramate, levetiracetam, and in triple combination with oxcarbazepine and lacosamide. Concomitant administration of
carbonic anhydrase inhibitors increases the risk of nephrolithiasis. When sulthiame and primidone are combined, children can
develop dizziness, unsteady gait, and drowsiness. Phenobarbital delays the onset of action of vigabatrin.

Keywords: drug interactions, antiepileptic drugs, concentration

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kořístková B, Grundmann M. Antiepileptic drug interactions. Part 1: Mutual interactions between antiepileptic drugs. Klin Farmakol Farm. 2016;30(4):19-23. doi: 10.36290/far.2016.030.
Download citation

References

  1. Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)-Part1: Pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 2013; 52: 927-966. Go to original source... Go to PubMed...
  2. Grundmann M, Kacířová I. Terapeutické monitorování hladin antiepileptik I. - obecné zásady, "stará" antiepileptika. Klin Farmakol Farm 2016; 30(2): 9-15. Go to original source...
  3. Kacířová I, Grundmann M. Terapeutické monitorování hladin antiepileptik II. - "nová" antiepileptika, speciální skupiny pacientů. Klin Farmakol Farm 2016; 30(2): 16-22. Go to original source...
  4. Patsalos PN. Antiepileptic drug interactions. A clinical guide. 2nd ed. London, UK: Springer, 2013: 437. Go to original source...
  5. Rambeck B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet 1996; 31: 309-324. Go to original source... Go to PubMed...
  6. Bruni J, Wilder BJ, Perchalski RJ, Hammond EJ, Villarreal HJ. Valproic acid and plasma levels of phenobarbital. Neurology 1980; 30: 94-97. Go to original source... Go to PubMed...
  7. Patel IH, Levy RH, Cutler RE. Phenobarbital-valporic acid interaction. Clin Pharmacol Ther 1980; 27: 515-521. Go to original source...
  8. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet 1995; 29: 341-369. Go to original source... Go to PubMed...
  9. Radulovic LL, Wilder BJ, Leppik IE, et al. Lack of interaction of gabapentin with carbamazepine or valproate. Epilepsia 1994; 35: 155-61; Erratum Epilepsia 1994; 35: 707. Go to original source...
  10. Khoo KC, Mendels J, Rothbart M, et al. Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam. Clin Pharmacol Ther 1980; 28: 368-375. Go to original source...
  11. Sackellares JC, Sato S, Dreifuss FE, Penry JK. Reduction of steady-state valproate levels by other antiepileptic drugs. Epilepsia 1981; 22: 437-441. Go to original source...
  12. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I. Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin Pharmacokinet. 1995; 29: 257-286. Go to original source... Go to PubMed...
  13. Gidal BE, Sheth R, Parnell J, Maloney K, Sale M. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res 2003; 57: 85-93. Go to original source...
  14. Bobčíková P, Brozmanová H, Grundmann M. Vzájemné interakce antiepileptik a jejich vliv na koncentraci účinných metabolitů epoxy - karbamazepinu a PEMY. Čs. fyziol. 1998; 47: 146.
  15. May TW, Boor R, Rambeck B, Jürgens U, Korn-Merker E, Brandt C. Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2011; 33: 214-121. Go to original source... Go to PubMed...
  16. Chu XM, Zhang LF, Wang GJ, Zhang SN, Zhou JH, Hao HP. Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur J Clin Pharmacol 2012; 68: 1395-1401. Go to original source...
  17. Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem Pharmacol 2003; 65: 1441-1449. Go to original source... Go to PubMed...
  18. Jiang D, Bai X, Zhang Q, Lu W, Wang Y, Li L, Muller M. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinearmixed-effect modeling. Eur J Clin Pharmacol 2009; 65: 1187-1193. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.